Clinical Trials Browser

Phase 2/3 × INDUSTRY × Cholangiocarcinoma × Clear all

NCT05506943 2026-05-07

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Phase 2/3 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06506955 2026-04-03

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT02807181 2025-05-09

SIRCCA

Phase 2/3 Terminated

89 enrolled 23 charts

Gastrointestinal

Cholangiocarcinoma

NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Phase 2/3 Terminated

309 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05429697 2022-09-27

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Phase 2/3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03086993 2022-03-24

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Phase 2/3 Unknown

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma